Drugs / PEP
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06463132 | Nov 2024 → Nov 2025 | osteoarthritis, knee | Rion Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06463132 ↗ |
| Modality | Other / unclassified | “Purified Exosome Product” NCT06463132 ↗ |
| Route | Other | “single intra-articular injections of PEP reconstituted with 0.9% Normal Saline at a low dose (one vial PEP) and high dose (two vials PEP), with and without EUFLEXXA” NCT06463132 ↗ |